|Last Price||Today's Change||52-Week Range||Trading Volume|
|51.21||0.00 (0.00%)||31.85 - 53.68||46.9 thousand (Below Avg)|
Market data as of 12:00AM 12/09/13. Quotes are delayed by at least 15 min.
Four-Year Data from Phase 3 DASISION Trial Comparing Sprycel® (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Presented at Annual Meeting of the American Society of Hematology
12/09/2013 6:30 PM ET